News

media

Nov 12, 2021

SF Business Times

Peninsula biotech looks to 'click' fresh $50M into new approach against cancer

press

Nov 11, 2021

Press release

Shasqi Raises $50 Million to Expand Click Chemistry Platform Beyond Injectable Tumors and Accelerate Lead Clinical Program

media

Nov 11, 2021

Endpoints News

Investors bet on small biotech's mission

media

Nov 11, 2021

Fierce Biotech

Shasqi snatches $50M Series B

media

Nov 10, 2021

Bioworld

Shasqi poster presentations at ESMO 2021

press

Nov 4, 2021

Press Release

Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings

conference

Oct 20, 2021

2021 - CTOS - Clinical Poster

First-in-human trial of SQ3370 in relapsed or refractory soft tissue sarcoma and other solid tumors: proof-of-concept for the click chemistry- based CAPAC platform

conference

Oct 18, 2021

2021 - CTOS - Preclinical Poster

Click Activated Protodrugs Against Cancer (CAPAC) Platform Enhances Antitumor Efficacy, Safety and Pharmacokinetics of Cancer Therapeutics

conference

Oct 17, 2021

2021 - SITC - Preclinical Poster

Combination of click chemistry-based SQ3370 with immunotherapies enhances antitumor effect in murine tumors with minimized systemic toxicity

conference

Oct 13, 2021

2021 - SITC - Clinical Poster

Pharmacokinetic and immunologic data from a Phase I study of the click chemistry-based therapy SQ3370 in advanced solid tumors and soft-tissue sarcoma provides proof-of-concept for the CAPAC platform

press

Sep 16, 2021

Press Release

Shasqi Presents Initial Data Validating Approach of Click Chemistry Activated Oncology Therapeutics at ESMO Congress 2021

conference

Aug 29, 2021

2021 - ESMO - Clinical Poster

Early pharmacokinetic data from a Phase I study of SQ3370 (NCT04106492) in patients with advanced solid tumors provides proof-of-concept for the click chemistry-based CAPAC platform